SCHEMBL24251979

SCHEMBL24251979

C#Cc1ccc2sc(C)nc2c1

nearest known ligand 0.52

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 5/20 0.52
ALDH1A1 P00352 5/20 0.52
NPC1 O15118 4/20 0.52
RAB9A P51151 4/20 0.52
HSD17B10 Q99714 2/20 0.52
TP53 P04637 2/20 0.52
MAPT P10636 2/20 0.52
PKM P14618 1/20 0.52
HPGD P15428 1/20 0.52
GAA P10253 2/20 0.48
KMT2A Q03164 1/20 0.46
POLB P06746 1/20 0.45
DYRK1A Q13627 1/20 0.45
LMNA P02545 2/20 0.40
NPSR1 Q6W5P4 1/20 0.40
HTT P42858 2/20 0.39
CASP3 P42574 1/20 0.39
SENP7 Q9BQF6 1/20 0.39
TRPV1 Q8NER1 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7380470 0.82 SMN1; SMN2 (0.52) SMN1; SMN2ALDH1A1NPC1RAB9AHSD17B10
SCHEMBL24251985 0.78 NPC1 (0.58) SMN1; SMN2NPC1RAB9AHSD17B10TP53
SCHEMBL10987723 0.76 DYRK1A (0.55) SMN1; SMN2ALDH1A1NPC1RAB9ATP53
SCHEMBL92781 0.75 SMN1; SMN2 (0.61) SMN1; SMN2ALDH1A1NPC1RAB9AHSD17B10
SCHEMBL26087314 0.75 DYRK1A (0.40) HPGDDYRK1ATRPV1
SCHEMBL20887514 0.75 ABL1 (0.58) SMN1; SMN2ALDH1A1NPC1RAB9AHSD17B10
SCHEMBL1852823 0.73 GAA (0.50) SMN1; SMN2ALDH1A1NPC1RAB9AHSD17B10
SCHEMBL24251981 0.73 NPC1 (0.49) ALDH1A1NPC1RAB9AHSD17B10TP53
SCHEMBL11086967 0.73 KDM4E (0.54) SMN1; SMN2ALDH1A1NPC1RAB9AHSD17B10
Bromide SCHEMBL10996884 0.73 SMN1; SMN2 (0.59) SMN1; SMN2ALDH1A1NPC1RAB9AHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230303575-A1 FGFR AND MUTATION INHIBITOR THEREOF, PREPARATION METHOD THEREFOR AND USE THEREOF ABBISKO THERAPEUTICS CO., LTD. (CN) 2023-09-28 US disclosed
US-20230303575-A1 FGFR AND MUTATION INHIBITOR THEREOF, PREPARATION METHOD THEREFOR AND USE THEREOF ABBISKO THERAPEUTICS CO., LTD. (CN) 2023-09-28 US disclosed
EP-4169922-A1 FGFR AND MUTATION INHIBITOR THEREOF, AND PREPARATION METHOD THEREFOR AND USE THEREOF Abbisko Therapeutics Co., Ltd. (CN) 2023-04-26 EP disclosed
WO-2022033532-A1 FGFR AND MUTATION INHIBITOR THEREOF, AND PREPARATION METHOD THEREFOR AND USE THEREOF 上海和誉生物医药科技有限公司 2022-02-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230303575-A1 FGFR AND MUTATION INHIBITOR THEREOF, PREPARATION METHOD THEREFOR AND USE THEREOF FGFR3, FGFR1, FGFR4 SMN1; SMN2 4222/4885ALDH1A1 1092/4885NPC1 2173/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.